NRF2 and cancer: the good, the bad and the importance of context
Open accessThe DOI matches its Crossref record; 119 of the 120 references it cites were found in a registry or an index.
Abstract
Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NRF2 is activated and overexpressed in cancer to promote cancer cell survival; the cellular antioxidant system is largely regulated by NRF2 and its associated genes.30”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [30]
In the citing paper
“Furthermore, increased ROS levels facilitate the activation of HIF1α and NRF2 transcription factors, thus promoting transcriptional programs that further contribute to tumorigenesis (Bertout et al., 2008; Sporn and Liby, 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Sporn and Liby, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedPhosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2
Jain, A. K., Mahajan, S., & Jaiswal, A. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709854200 · Cited by 49
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Cited by
Items 401–500 of 1,000
Allelic imbalance of somatic mutations in cancer genomes and transcriptomes
Rhee, J., Lee, S., Park, W., Kim, Y.-H., & Kim, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-01966-z · Cited by 52
Sabzichi, M., Mohammadian, J., Bazzaz, R., Pirouzpanah, M. B., Shaaker, M., Hamishehkar, H., Chavoshi, H., Salehi, R., & Samadi, N. (2017) · Process Biochemistry · doi:10.1016/j.procbio.2017.05.024 · Cited by 47
β-TrCP1 Is a Vacillatory Regulator of Wnt Signaling
Long, M. J. C., Lin, H., Parvez, S., Zhao, Y., Poganik, J. R., Huang, P., & Aye, Y. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.06.009 · Cited by 49
Oxidative stress and metabolic reprogramming in Cr(VI) carcinogenesis
Clementino, M., Shi, X., & Zhang, Z. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.11.015 · Cited by 52
Moradi‐Marjaneh, R., Hassanian, S. M., Mehramiz, M., Rezayi, M., Ferns, G. A., Khazaei, M., & Avan, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27881 · Cited by 48
“Although studies report that the Nrf2 can defend cells against oxidative stress, it seems that this compound plays a paradoxical role in tumorigenesis (Sporn & Liby, 2012).”
BackgroundA Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy
Zhang, D., Hou, Z., Aldrich, K. E., Lockwood, L. R., Odom, A. L., & Liby, K. T. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0210 · Cited by 47
Self-citationThe KEAP1-NRF2 System and Esophageal Cancer
Hirose, W., Oshikiri, H., Taguchi, K., & Yamamoto, M. P. (2022) · Cancers · doi:10.3390/cancers14194702 · Cited by 49
A state-of-the-art review on the NRF2 in Hepatitis virus-associated liver cancer
Kalantari, L., Ghotbabadi, Z. R., Gholipour, A., Ehymayed, H. M., Najafiyan, B., Amirlou, P., Yasamineh, S., Gholizadeh, O., & Emtiazi, N. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01351-6 · Cited by 48
“Therefore, it is debatable whether activating NRF2 or, conversely, inhibiting it is a beneficial method for cancer therapy or prevention [16].”
Athar, M., Lone, M. Y., Khedkar, V. M., & Jha, P. C. (2015) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2015.1077343 · Cited by 47
“…(HO-1), NAD(P)H quinoneoxidoreductase 1 (NQO1), glutamatecysteine ligase (GCL), that consists of both the modifier (GCLM) and catalytic (GCLC) subunits, and several members of the glutathione S-transferase family (de Vries et al., 2008; Ramsey et al., 2007; Sporn & Liby, 2012; Uttara et al., 2009).”
BackgroundMethodMolecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology
Su, D., Singer, E. A., & Srinivasan, R. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000186 · Cited by 46
Pan, M., Chiou, Y., Chen, L., & Ho, C. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201400515 · Cited by 46
Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex
Bello, M., & Morales‐González, J. A. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.07.117 · Cited by 46
“Disrupting the Keap1-Nrf2 pathway enhances Nrf2 activity, which has been identified as an important approach for the prevention of different chronic diseases in which oxidative stress and inflammation are present, such as cancer, diabetes, Alzheimer’s and Parkinson’s.”
BackgroundInfluentialRajesh, Y., Biswas, A., Kumar, U., Das, S., Banerjee, I., Banik, P., Bharti, R., Nayak, S., Ghosh, S. K., & Mandal, M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.025 · Cited by 45
Xie, Y., Zhang, X., Zhang, C., Yang, Y., He, J., & Chen, Y. (2019) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13146 · Cited by 47
Fagundes, F. L., Pereira, Q. C., Zarricueta, M. L., & dos Santos, R. D. C. (2021) · Nutrients · doi:10.3390/nu13103312 · Cited by 57
“Nuclear erythroid factor 2-related factor 2 (NRF2) is a transcription factor associated with antioxidant enzymes, which plays a master role in redox homeostasis in the cells [58].”
BackgroundARE-PROTACs Enable Co-degradation of an Nrf2–MafG Heterodimer
Ji, J., Ma, S., Zhu, Y., Zhao, J., Tong, Y., You, Q., & Jiang, Z. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01909 · Cited by 48
Okano, Y., Nezu, U., Enokida, Y., Lee, M. T. M., Kinoshita, H., Lezhava, A., Hayashizaki, Y., Morita, S., Taguri, M., Ichikawa, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073794 · Cited by 45
“In fact, mutations in the NRF2 and KEAP1 genes have been found in carcinomas of the lung [12], breast [48], liver [49], and stomach [49].”
BackgroundYoon, D. S., Choi, Y., Cha, D. S., Zhang, P., Choi, S. M., Alfhili, M. A., Polli, J. R., Pendergrass, D., Taki, F., Kapalavavi, B., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12719-3 · Cited by 49
Metabolic reprogramming of the tumor microenvironment by p62 and its partners
Reina‐Campos, M., Shelton, P. M., Díaz-Meco, M. T., & Moscat, J. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.010 · Cited by 49
Jiang, Z., Lu, M., & You, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01121 · Cited by 46
Tang, C., Tan, S., Zhang, Y., Dong, L., & Xu, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.032 · Cited by 49
Renu, K., & Gopalakrishnan, A. V. (2019) · Reproductive Biology · doi:10.1016/j.repbio.2019.02.004 · Cited by 49
Harnessing altered oxidative metabolism in cancer by augmented prooxidant therapy
Firczuk, M., Bajor, M., Graczyk‐Jarzynka, A., Fidyt, K., Góral, A., & Zagożdżon, R. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.037 · Cited by 46
Nrf2/P–glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer
Sadeghi, M. R., Jeddi, F., Soozangar, N., Somi, M. H., Shirmohamadi, M., Khaze, V., & Samadi, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.062 · Cited by 44
The indirect antioxidant sulforaphane protects against thiopurine-mediated photooxidative stress
Benedict, A. L., Knatko, E. V., & Dinkova-Kostova, A. T. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs293 · Cited by 44
Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress
Zhang, S., Duan, S., Xie, Z., Bao, W., Xu, B., Yang, W., & Zhou, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924817 · Cited by 64
“As mentioned above, NRF2/KEAP1 signaling commonly acts as cellular defensive machinery under oxidative stress, which is a vital factor correlated with neoplastic diseases (Sporn and Liby, 2012; Rojo de la Vega et al., 2018).”
BackgroundThe molecular biology and therapeutic potential of Nrf2 in leukemia
Khodakarami, A., Adibfar, S., Karpisheh, V., Abolhasani, S., Jalali, P., Mohammadi, H., Navashenaq, J. G., Hojjat‐Farsangi, M., & Jadidi‐Niaragh, F. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02660-5 · Cited by 47
Chen, F., Liu, Y., Wang, S., Guo, X., Shi, P., Wang, W., & Xu, B. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.122 · Cited by 45
Surya, R., Héliès‐Toussaint, C., Martin, O. C. B., Gauthier, T., Guéraud, F., Taché, S., Naud, N., Jouanin, I., Chantelauze, C., Durand, D., et al. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw035 · Cited by 49
“Nrf2 [nuclear factor (erythroid derived 2)-like 2] is a transcription factor that has been shown to regulate the expression of cellular detoxifying and antioxidant enzymes (including those involved in HNE detoxification) through Nrf2-Keap1-ARE signaling pathway, thus exerting cytoprotective properties against oxidativ…”
BackgroundHu, H., Hao, L., Tang, C.-Z., Zhu, Y., Jiang, Q., & Yao, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.078 · Cited by 44
Gana, C. C., Hanssen, K. M., Yu, D. M. T., Flemming, C. L., Wheatley, M. S., Conseil, G., Cole, S. P. C., Norris, M. D., Haber, M., & Fletcher, J. I. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.07.009 · Cited by 45
Bovilla, V. R., Kuruburu, M. G., Bettada, V. G., Krishnamurthy, J., Sukocheva, O. A., Thimmulappa, R. K., Shivananju, N. S., Balakrishna, J. P., & Madhunapantula, S. V. (2021) · Biomedicines · doi:10.3390/biomedicines9091119 · Cited by 50
“Supporting this hypothesis, constitutive Nrf2 activation was shown to defend malignant cells against oxidative stress [101].”
BackgroundOshi, M., Angarita, F. A., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12123856 · Cited by 46
“To this end, high levels of NRF2 are generally correlated with poor prognosis in multiple types of cancer [5,6].”
Jamieson, S. M. F., Gu, Y., Manesh, D. M., El‐Hoss, J., Jing, D., MacKenzie, K. L., Guise, C. P., Foehrenbacher, A., Pullen, S. M., Benito, J., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.019 · Cited by 45
Kwon, O.-S., Kwon, E.-J., Kong, H., Choi, J., Kim, Y. J., Lee, E., Kim, W., Lee, H., & Cha, H. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101719 · Cited by 45
“Thus, cancer cells may adapt to a high-ROS environment through the induction of anti-oxidant mechanisms, including KEAP1-NRF2 [68, 69], which is why NRF2 has been studied as a promising molecular target within advanced cancers.”
BackgroundYin, X., He, X., Wu, L., Yan, D., & Yan, S. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4566949 · Cited by 42
Gjyshi, O., Flaherty, S., Veettil, M. V., Johnson, K. E., Chandran, B., & Bottero, V. (2015) · Journal of Virology · doi:10.1128/jvi.02742-14 · Cited by 42
“This allows for stabilization of Nrf2, which then translocates into the nucleus, binds to antioxidant response elements (ARE) in the promoter regions of more than 200 genes, and activates the transcription of a battery of antioxidant and cytoprotective genes involved in glutathione synthesis, elimination of reactive o…”
BackgroundTranscription factors: Time to deliver
Ulasov, A. V., Rosenkranz, A. A., & Sobolev, A. S. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.004 · Cited by 45
Verma, A. K., Yadav, A., Singh, S. V., Mishra, P., & Rath, S. K. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.02.037 · Cited by 42
Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice
Zhang, D., Rennhack, J. P., Andrechek, E. R., Rockwell, C. E., & Liby, K. T. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7201 · Cited by 45
“All of these genetic and epigenetic alterations result in constitutively high levels of Nrf2 expression and activity, which is associated with chemoresistance and poor prognosis (50, 71, 76).”
Self-citationNrf2 regulates CD4+ T cell–induced acute graft-versus-host disease in mice
Tsai, J. J.-Y., Velardi, E., Shono, Y., Argyropoulos, K. V., Holland, A. M., Smith, O. M., Yim, N. L., Rao, U. K., Kreines, F. M., Lieberman, S. R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-812941 · Cited by 43
Geniposide attenuates cadmium‑induced oxidative stress injury via Nrf2 signaling in osteoblasts
He, T., Shen, H., Zhu, J., Zhu, Y., He, Y., Li, Z., & Lu, H.-X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10396 · Cited by 45
Kachuri, L., Johansson, M., Rashkin, S. R., Graff, R. E., Bossé, Y., Manem, V. S., Caporaso, N. E., Landi, M. T., Christiani, D. C., Vineis, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13855-2 · Cited by 50
“Histology Adenocarcinoma 11273 (39) Squamous cell carcinoma 7426 (35) Small cell carcinoma 2664 (9) Total 29266 (100) 56,450 (100)”
BackgroundWang, X., Ye, T., Xue, B., Yang, M., Li, R., Xu, X., Zeng, X. Y., Tian, N., Bao, L., & Huang, Y. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01111-2 · Cited by 44
Ferroptosis: a new unexpected chance to treat metastatic melanoma?
Gagliardi, M., Saverio, V., Monzani, R., Ferrari, E., Piacentini, M., & Corazzari, M. (2020) · Cell Cycle · doi:10.1080/15384101.2020.1806426 · Cited by 49
Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries
Rocha, C. R. R., Rocha, A. R., Silva, M. M., Gomes, L. R., Latância, M. T., Andrade-Tomaz, M., de Souza, I., Monteiro, L. K. S., & Menck, C. F. M. (2020) · Cells · doi:10.3390/cells9122573 · Cited by 45
“For the input gene list of NRF2 targets (GSK3B, UBE2E3, UBE2E1, GSTP1, NFE2L2, SQSTM1, MAFB, HMOX1, SIAH2, GSTM4, SRXN1, CASP3, GNAI1, COL3A1, ABCC3, PLEKHH2, GCLM, SLC7A2), the software calculates the prognostic index (PI), also known as the risk score, for each sample.”
BackgroundInfluentialFahrmann, J. F., Tanaka, I., Irajizad, E., Mao, X., Dennison, J. B., Murage, E. N., Casabar, J. P., Mayo, J., Peng, Q., Çeliktaş, M., et al. (2022) · Cancers · doi:10.3390/cancers14102543 · Cited by 45
Nrf2 is essential for timely M phase entry of replicating hepatocytes during liver regeneration
Zou, Y., Hu, M., Lee, J., Nambiar, S. M., Garcia, V., Bao, Q., Chan, J. Y., & Dai, G. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00332.2014 · Cited by 42
“Nrf2 is highly activated in various tumor cells and promotes their proliferation through poorly understood mechanisms (31).”
BackgroundThe Redox Paradox: Cancer’s Double-Edged Sword for Malignancy and Therapy
Ranbhise, J. S., Singh, M. K., Ju, S., Han, S., Yun, H. R., Kim, S. S., & Kang, I. (2025) · Antioxidants · doi:10.3390/antiox14101187 · Cited by 50
“LOF mutations are documented in lung, gallbladder, ovary, breast, liver, and stomach carcinomas [57].”
GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma
Hayashi, M., Guida, E., Inokawa, Y., Goldberg, R. L., Reis, L. O., Ooki, A., Pilli, M., Sadhukhan, P., Woo, J., Choi, W., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aba0443 · Cited by 42
“However, constitutive activation of NRF2 signaling can also be a deleterious switch that protects cancer cells from oxidative stress, thereby promoting their proliferation (33).”
BackgroundUnfolding Nrf2 in diabetes mellitus
Behl, T., Kaur, I., Sehgal, A., Sharma, E., Kumar, A., Grover, M., & BUNGAU, S. G. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06081-3 · Cited by 47
The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis
Occhiuto, C. J., Moerland, J. A., Leal, A. S., Gallo, K. A., & Liby, K. T. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.2191 · Cited by 46
“Despite significant advances in the NRF2 field over the past decade (Pillai et al., 2022; Robledinos-Antón et al., 2019; Rojo de la Vega et al., 2018; Sporn and Liby, 2012; Wu et al., 2019; Zimta et al., 2019), a consensus on the precise role for NRF2 throughout carcinogenesis remains elusive.”
Self-citationClinicopathologic significance of CXCR4 and Nrf2 in colorectal cancer
Tinghua, H., Yu, Y., Shuo, Y., Hui, G., Lili, H., Wenjuan, W., Tao, T., Yibin, H., Zhiyan, L., Kejun, N., et al. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130069 · Cited by 40
Funes, J. M., Henderson, S. R., Kaufman, R., Flanagan, J. M., Robson, M. P., Pedley, B. R., Moncada, S., & Boshoff, C. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-20 · Cited by 44
“Indeed, it has been suggested that the role of Nrf2 in cancer is context-dependent [54].”
BackgroundExcess homocysteine upregulates the NRF2-antioxidant pathway in retinal Müller glial cells
Navneet, S., Cui, X., Zhao, J., Wang, J., Kaidery, N. A., Thomas, B., Bollinger, K. E., Yoon, Y., & Smith, S. B. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.03.022 · Cited by 43
Le, H. V., Babak, M. V., Ehsan, M. A., Altaf, M., Reichert, L., Gushchin, A. L., Ang, W. H., & Isab, A. A. (2020) · Dalton Transactions · doi:10.1039/d0dt01411g · Cited by 40
Yang, J., Fu, X. B., Liao, X., & Li, Y. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.561998 · Cited by 45
“Under physiological conditions, Nrf2 is coupled with Kelch-like ECH-associated protein 1 (Keap1) and exists in the cytoplasm in an inactive form, which is then rapidly degraded by the ubiquitin-proteasome system, thereby maintaining stable expression of Nrf2 (20).”
BackgroundClinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma
Chen, J., Yu, Y., Ji, T., Ma, R., Chen, M., Li, G., Li, F., Ding, Q. J., Kang, Q., Huang, D., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.788 · Cited by 39
“In the oxidative stress pathway, there are two very important molecules, transcription factor nuclear factor erythroid 2related factor 2 (Nrf2) and Kelchlike ECHassociated protein1 (Keap1) [7].”
BackgroundHaque, E., Karim, M. R., Teeli, A. S., Śmiech, M., Leszczyński, P., Winiarczyk, D., Parvanov, E. D., Atanasov, A. G., & Taniguchi, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155378 · Cited by 40
“This issue has been discussed very intensively in several reviews [14,125] and an excellent hypothesis is proposed by Sporn and his group that the role of NRF2 can be altered depending on the stage of tumor progression [126].”
BackgroundZhou, S., Wang, Y., Yang, Y., He, Z., Zhao, R., Zhe, H., Zhang, X., Pan, S., Duan, W., Yang, T., et al. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s73493 · Cited by 45
Trivedi, M. S., Singh, A., Talekar, M., Pawar, G. N., Shah, P., & Amiji, M. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-02816-8 · Cited by 41
He, X., Zhou, Y., Chen, W., Zhao, X., Duan, L., Zhou, H., Li, M., Yin, Y., Zhao, J., Guo, Y., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02636-3 · Cited by 42
“NRF2 is involved in the control of antioxidant molecules in cells [30].”
BackgroundRenal cell carcinoma: translational aspects of metabolism and therapeutic consequences
Yang, O. C. Y., Maxwell, P. H., & Pollard, P. J. (2013) · Kidney International · doi:10.1038/ki.2013.245 · Cited by 41
Cong, Z., Wang, H., Wang, J., Zhou, Y., Pan, H., Zhang, D.-D., & Zhu, L. (2013) · Oncology Reports · doi:10.3892/or.2013.2485 · Cited by 42
“Nrf2 activation is associated with preventing many types of human diseases such as cancer, ischemia, hyperoxia, inflammatory diseases, neurodegenerative diseases, diabetes and obesity (11,15-21).”
BackgroundDiminished stress resistance and defective adaptive homeostasis in age-related diseases
Lomeli, N., Bota, D. A., & Davies, K. J. A. (2017) · Clinical Science · doi:10.1042/cs20160982 · Cited by 41
Orrù, C., Szydlowska, M., Taguchi, K., Zavattari, P., Perra, A., Yamamoto, M., & Columbano, A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.010 · Cited by 38
Wang, C., Huang, W., Lin, J., Fang, F., Wang, X., & Wang, H. (2019) · Chemosphere · doi:10.1016/j.chemosphere.2019.125086 · Cited by 41
Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
Liu, Y., Pang, Y. K., Caisová, V., Ding, J., Yu, D., Zhou, Y., Huynh, T., Ghayee, H. K., Pacák, K., & Yang, C. (2020) · Cancers · doi:10.3390/cancers12020280 · Cited by 42
“Owing to the close relevance to therapeutic resistance and detoxification pathways, targeting NRF2 has long been proposed as a potential cancer therapeutic approach [22,23].”
BackgroundMAFG-driven osteosarcoma cell progression is inhibited by a novel miRNA miR-4660
Shan, H., Zhu, L., Yao, C., Zhang, Z.-Q., Liu, Y.-Y., Jiang, Q. L., Zhou, X., Wang, X., & Cao, C. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.03.006 · Cited by 44
Hippo Pathway in Regulating Drug Resistance of Glioblastoma
Casati, G., Giunti, L., Iorio, A. L., Marturano, A., Galli, L., & Sardi, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413431 · Cited by 51
Roles of NRF2 in Fibrotic Diseases: From Mechanisms to Therapeutic Approaches
Hao, W., Li, M., Cai, Q., Wu, S., Li, X., He, Q., & Hu, Y. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.889792 · Cited by 47
“In contrast, for malignant conditions such as tumors, NRF2 can be inhibited to weaken the adaptive capacity of cells to oxidative stress and enhance the therapeutic effect of chemotherapy drugs, thus inhibiting disease progression (Sporn and Liby, 2012).”
BackgroundRole of Nrf2 in Cancer Photodynamic Therapy: Regulation of Human ABC Transporter ABCG2
Ishikawa, T., Kajimoto, Y., Sun, W. Y., Nakagawa, H., Inoue, Y., Ikegami, Y., Miyatake, S., & Kuroiwa, T. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23563 · Cited by 41
The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma
Ozyerli‐Goknar, E., Sur‐Erdem, İ., Seker-Polat, F., Cingöz, A., Kayabölen, A., Kahya, Z., Uyulur, F., Gezen, M., Tolay, N., Erman, B., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2107-y · Cited by 38
Escoll, M., Lastra, D., Pajares, M., Robledinos-Antón, N., Rojo, A. I., Fernández-Ginés, R., Mendiola, M., Martínez-Marín, V., Esteban, I., López‐Larrubia, P., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2019.101425 · Cited by 40
Zhang, X., Li, T., Gong, E. S., & Liu, R. H. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c03202 · Cited by 37
Escin activates AKT-Nrf2 signaling to protect retinal pigment epithelium cells from oxidative stress
Wang, K., Jiang, Y., Wang, W., Ma, J., & Chen, M. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.117 · Cited by 40
A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer
Lucki, N. C., Villa, G. R., Vergani, N., Bollong, M. J., Beyer, B. A., Lee, J. W., Anglin, J. L., Spangenberg, S. H., Chin, E. N., Sharma, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816626116 · Cited by 37
Redox Regulation of Nrf2 in Cisplatin-Induced Kidney Injury
Mapuskar, K. A., Pulliam, C. F., Zepeda‐Orozco, D., Griffin, B. R., Furqan, M., Spitz, D. R., & Allen, B. G. (2023) · Antioxidants · doi:10.3390/antiox12091728 · Cited by 48
“…homeostasis by regulating the induction of a wide array of antioxidants and drug-metabolizing enzymes including superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), hemoxygenase (HO-1), NAD(P)H Quinone Dehydrogenase 1 (NQO-1), and glutathione S-transferase (GST) [23,25,26].”
Gupta, S. D., Sae‐tan, S., Wahler, J., So, J. Y., Bak, M. J., Cheng, L. C., Lee, M., Lin, Y., Shih, W. J., Shull, J. D., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0154 · Cited by 40
Wei, J., Zhu, H., Lord, G., Bhattachayya, M., Jones, B., Allaway, G. P., Biswal, S. S., Korman, B. D., Marangoni, R. G., Tourtellotte, W. G., et al. (2016) · Translational research · doi:10.1016/j.trsl.2016.12.002 · Cited by 40
“Because Nrf2 promotes cell survival under stress, increased Nrf2 activity could potentially promote cancer cell survival; and loss-of-function mutations in KEAP1 have been found in carcinomas with constitutive Nrf2 activity.(56) Several oncogenes, including KRAS, BRAF, and MYC, increase Nrf2 transcription and activity…”
Zhang, B., Fan, X., Wang, Z., Zhu, W., & Li, J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.048 · Cited by 36
RetracteddCK negatively regulates the NRF 2/ ARE axis and ROS production in pancreatic cancer
Hu, Q., Qin, Y., Xiang, J., Liu, W., Xu, W., Sun, Q., Ji, S., Liu, J., Zhang, Z., Ni, Q., et al. (2018) · Cell Proliferation · doi:10.1111/cpr.12456 · Cited by 38
Cai, L., Jin, X., Zhang, J., Li, L., & Zhao, J. (2020) · Aging · doi:10.18632/aging.103777 · Cited by 40
Wu, X., Huang, L., & Liu, J. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10110 · Cited by 41
“Keap1 contains five domains: i) An N‐terminal region domain; ii) a bric á brac (BTB) dimerization domain; iii) an intervening region (IVR) domain; iv) a theme containing the six Kelch motifs; and v) a C‐terminal region domain (32).”
BackgroundMetabolic response to radiation therapy in cancer
Read, G. H., Bailleul, J., Vlashi, E., & Kesarwala, A. H. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23379 · Cited by 43
“that contain antioxidant response elements (ARE) largely involved in maintaining cellular redox homeostasis.(127,128) Among NRF2's target”
BackgroundWang, S., & Qi, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.916653 · Cited by 46
Sun, S., Yu, M., Liu, Y., Huang, W., Zhu, M., Fu, Y., Yan, L., Wang, Q., Ji, X., Zhao, J., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122068 · Cited by 35
Park, J., Choi, J. H., Ju, E. M., Pae, A. N., & Park, K. D. (2015) · Molecules · doi:10.3390/molecules200915989 · Cited by 38
“The transcription factor Nrf2 regulates oxidative stress responses by inducing expression of antioxidant enzyme genes such as heme oxygenase 1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), glutamate-cysteine ligase (GCL), which consists of both the modifier (GCLM) and catalytic (GCLC) subunits [9,10].”
BackgroundRoy, R. V., Pratheeshkumar, P., Son, Y.-O., Wang, L., Hitron, J. A., Divya, S. P., Zhang, Z., & Shi, X. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.07.016 · Cited by 35
“In contrast, constitutive expression of Nrf2 is carcinogenic due to its protection of cancer cells against oxidative stress and chemotherapeutic agents (Tullet et al., 2008; Inami et al., 2011; Sporn and Liby, 2012; Son et al., 2014; Son et al., 2015b).”
BackgroundNeuroglobin: A Novel Player in the Oxidative Stress Response of Cancer Cells
Fiocchetti, M., Fernandez, V. S., Montalesi, E., & Marino, M. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6315034 · Cited by 37
“Some evidence addresses NRF-2 as a tumor suppressor function in normal and premalignant cells, according to the role of oxidative stress on cancer onset [4, 70].”
BackgroundSquamous Transition of Lung Adenocarcinoma and Drug Resistance
Hou, S., Han, X., & Ji, H. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.08.002 · Cited by 34
Lee, J., Pandey, A. K., Venkatesh, S., Thilagavathi, J., Honda, T., Singh, K. D., & Suzuki, C. K. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101719 · Cited by 40
Oxidative Stress Linking Obesity and Cancer: Is Obesity a ‘Radical Trigger’ to Cancer?
Jovanović, M., Kovačević, S., Brkljačić, J. M., & Djordjevic, A. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098452 · Cited by 44
“Nrf2 is found upregulated in different types of cancer; the increased expression is considered essential to cancer cell proliferation and tumorigenesis and in correlation with tumor malignancy (Figure 4) [85,96].”
BackgroundAboukhatwa, S. M., Sidhom, P. A., Angeli, A., Supuran, C. T., & Tawfik, H. O. (2023) · ACS Omega · doi:10.1021/acsomega.2c07285 · Cited by 34
Martínez, V. D., Vucic, E. A., Thu, K. L., Pikor, L. A., Hubaux, R., & Lam, W. L. (2014) · BioMed Research International · doi:10.1155/2014/159459 · Cited by 40
Inhibition of SGK1 confers vulnerability to redox dysregulation in cervical cancer
Wang, M., Xue, Y., Shen, L., Qin, P., Sang, X., Tao, Z., Yi, J., Wang, J., Liu, P., & Cheng, H.-L. M. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101225 · Cited by 35
Wang, P., Luo, L., Shen, Q., Shi, G., Mohammed, A., Ni, S., & Wu, X. Y. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.12.013 · Cited by 34
Wu, R., Zhang, H., Zhao, M., Li, J., Hu, Y., Fu, J., Pi, J., Wang, H., & Xu, Y. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113846 · Cited by 36
Zhong, J., Liu, F., Chen, R., Xu, J., Guo, D., Guo, C., Guo, C., Chen, J., Chen, C., & Wang, X. (2021) · Oncology Letters · doi:10.3892/ol.2021.12686 · Cited by 35
“It has been reported that several anticancer agents exert anticancer effects through inducing oxidative stress and via activation of the nuclear factor erythroid 2‐related factor 2 (Nrf2), a transcription factor that protects cells against oxida‐ tive stress (64).”
Khalili, F., Vaisi‐Raygani, A., Shakiba, E., Kohsari, M., Dehbani, M., Naseri, R., Asadi, S., Rahimi, Z., Rahimi, M., & Rahimi, Z. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24163 · Cited by 39
Metadata
- Authors
- Sporn, M. B., & Liby, K. T.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Sporn, Michael B.
- Liby, Karen T.
- ORCID
- Liby, Karen T.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-19
- Volume
- 12
- Issue
- 8
- Pages
- 564-571
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3836441
- OpenAlex
- W2030749349
- Cited by
- 1,067
- References
- 120
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 70 · 2023: 72 · 2022: 88 · 2021: 90 · 2020: 97 · 2019: 93 · 2018: 112 · 2017: 88 · 2016: 93 · 2015: 62 · 2014: 57 · 2013: 50 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA078814, P30CA023108)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Nrf2, chemoprevention, carcinogenesis, chemoresistance, transcription factor activation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Anticarcinogenic Agents, Tumor Suppressor Proteins, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.